Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan

Read full text
Authors: Yuki Goshima, Tomoya Saika, Yuki Kado, Michiko Yamazaki, Tohru Takebe, Shunsuke Yui
Cited by: 3
References: 19

Abstract

= 162) were clustered by mean daily VEN dose and dosing frequency, yielding four groups defined by high versus low dose and high versus low frequency. Treatment persistence was longer in the low-frequency clusters, where there was a clearer association with dosing frequency than with mean daily dose. Strong CYP3A4 inhibitor use was more common in low-dose clusters, consistent with dose adjustment when strong inhibitors are coadministered. These findings highlight heterogeneous real-world VEN use and its implications for treatment persistence.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Acute Lymphoblastic Leukemia research Retinoids in leukemia and cellular processes

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Publisher
Informa UK Limited
Volume
67
Issue
8
Pages
1788–1795
Publication date
22 May 2026
Language
EN